KBC Group NV Purchases 457,383 Shares of Boston Scientific Co. (NYSE:BSX)

KBC Group NV boosted its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 24.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,338,801 shares of the medical equipment provider's stock after purchasing an additional 457,383 shares during the quarter. Boston Scientific accounts for about 0.6% of KBC Group NV's investment portfolio, making the stock its 24th biggest holding. KBC Group NV owned about 0.16% of Boston Scientific worth $195,991,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Eagle Bay Advisors LLC increased its position in shares of Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 309 shares in the last quarter. First Foundation Advisors acquired a new position in Boston Scientific in the first quarter valued at about $25,000. Triad Wealth Partners LLC bought a new stake in shares of Boston Scientific in the second quarter worth about $26,000. Values First Advisors Inc. acquired a new stake in shares of Boston Scientific during the third quarter worth about $28,000. Finally, Andra AP fonden bought a new position in shares of Boston Scientific during the 2nd quarter valued at about $29,000. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

BSX has been the topic of several research analyst reports. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Thursday, October 31st. Stifel Nicolaus raised their price objective on shares of Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, October 18th. Bank of America upped their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. Mizuho lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Finally, Morgan Stanley upped their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an "overweight" rating in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $93.39.

Boston Scientific Stock Performance

NYSE BSX traded down $0.33 during trading on Thursday, reaching $88.44. 2,042,204 shares of the company's stock were exchanged, compared to its average volume of 6,050,874. Boston Scientific Co. has a fifty-two week low of $53.56 and a fifty-two week high of $89.30. The stock has a market capitalization of $130.35 billion, a P/E ratio of 73.36, a PEG ratio of 2.61 and a beta of 0.79. The business has a 50 day moving average price of $85.03 and a 200-day moving average price of $79.33. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to analysts' expectations of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm's revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.50 EPS. Sell-side analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the business's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the transaction, the executive vice president now directly owns 160,467 shares of the company's stock, valued at approximately $13,639,695. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 162,777 shares of the business's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now directly owns 1,572,096 shares of the company's stock, valued at $133,046,484.48. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 309,270 shares of company stock valued at $26,196,718 in the last three months. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.